Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2017-07-17 Board/Management Inform…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
XVIVO Perfusions CFO utnämnd till vice VD
Board/Management Information Classification · 98% confidence The document is a short press release (1723 characters) announcing a change in senior management: the CFO, Christoffer Rosenblad, has been appointed as Vice CEO while retaining his CFO role. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2017-07-17 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI–JUNI 2017' (Interim Report January-June 2017) for XVIVO Perfusion AB. It contains comprehensive financial statements, including income statements, EBITDA calculations, and management commentary on business performance for the second quarter and the first half of 2017. It is a substantive financial report covering a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2017
2017-07-14 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–JUNE 2017' and contains detailed financial statements, including income statements, EBITDA calculations, and management commentary for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2017
2017-07-14 English
Recruitment completed for PrimECC study
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "Press release" dated July 13, 2017, announcing the completion of recruitment for the PrimECC study. It discusses clinical trials, product development (PrimECC), patent status, and future publication timelines. This type of announcement, which is not a formal financial report (like 10-K or IR) but rather a general operational/clinical update released to the public and potentially mandated by market regulations (as indicated by the final paragraph referencing the EU Market Abuse Regulation), fits best under the general regulatory announcement category. Since it is not a specific financial report, management change, dividend notice, or shareholder vote result, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements not covered by more specific codes. The document length (4489 chars) is short, but it is an announcement of an event (recruitment completion) rather than an announcement of a report being attached, making RNS more suitable than RPA.
2017-07-13 English
PrimECC studien färdigrekryterad
Regulatory Filings Classification · 95% confidence The document is a press release dated July 13, 2017, announcing that patient recruitment for the 'PrimECC' clinical study has been completed. It discusses the study's purpose, the expected timeline for results publication (later in 2017), and mentions that the company is awaiting these results before a major product launch. The final paragraph explicitly states: "Denna information är sådan information som Xvivo Perfusion AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such information that Xvivo Perfusion AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.) This structure—a formal announcement of material, non-public information required by regulation—is characteristic of a general regulatory filing or announcement, rather than a specific financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Since it is a mandatory disclosure under MAR that doesn't fit the highly specific categories like DIRS, MANG, or DIV, the most appropriate general category is Regulatory Filings (RNS). The document length (4180 chars) is short, suggesting it is an announcement rather than the full underlying report.
2017-07-13 English
NOVEL-studien i USA med STEEN Solution™ och XPS™ färdigrekryterad
Regulatory Filings Classification · 95% confidence The document is a press release dated July 6, 2017, announcing the completion of patient recruitment for the NOVEL study in the USA, which is intended to support a PMA (Pre-Market Approval) application to the FDA. It discusses clinical trials, regulatory milestones (HDE approval, PMA application), and future steps (PAS study). This type of announcement, detailing progress on regulatory submissions or clinical trials that are not the final financial report or a formal proxy/shareholder vote result, typically falls under general regulatory announcements or investor relations updates. Since it is a formal announcement of a significant corporate/regulatory event, and it doesn't fit the specific definitions for ER, IR, 10-K, or CT, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the format and content (press release style), RNS is the most appropriate fallback for significant, non-financial, non-governance specific news.
2017-07-06 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.